Last reviewed · How we verify
Regadenoson MRI myocardial blood flow
Regadenoson is a selective adenosine A2A receptor agonist that increases coronary blood flow to enable assessment of myocardial perfusion during cardiac MRI imaging.
Regadenoson is a selective adenosine A2A receptor agonist that increases coronary blood flow to enable assessment of myocardial perfusion during cardiac MRI imaging. Used for Myocardial perfusion imaging via MRI for detection of coronary artery disease.
At a glance
| Generic name | Regadenoson MRI myocardial blood flow |
|---|---|
| Also known as | Regadenoson (Lexiscan), Prohance (Gadoteridol) |
| Sponsor | University of Colorado, Denver |
| Drug class | Adenosine A2A receptor agonist |
| Target | Adenosine A2A receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Regadenoson binds to adenosine A2A receptors on coronary vascular smooth muscle, causing vasodilation and increasing blood flow to the myocardium. This pharmacologic stress mimics the effect of exercise, allowing visualization of regional myocardial perfusion deficits on MRI without requiring physical exertion. The drug is used as a diagnostic agent to detect coronary artery disease and assess myocardial viability.
Approved indications
- Myocardial perfusion imaging via MRI for detection of coronary artery disease
Common side effects
- Headache
- Flushing
- Chest discomfort
- Dyspnea
- Dizziness
Key clinical trials
- The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study (NA)
- Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan Circulation
- Whole-Heart Myocardial Blood Flow Quantification Using MRI
- Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF (PHASE4)
- Perfusion Imaging With Myocardial Contrast Echocardiography in HCM (NA)
- Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies (NA)
- Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D) (PHASE4)
- Effects of Body Mass Index on the Hyperemic Response to Regadenoson (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: